Welcome to our dedicated page for Can-Fite BioPharma Ltd. news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. stock.
Can-Fite BioPharma Ltd. (CANF) is a clinical-stage biotechnology company whose news flow centers on the development of orally administered small-molecule drugs targeting the A3 adenosine receptor. On this page, readers can follow company announcements on clinical trial progress, regulatory designations, patent developments, financing events, and corporate actions related to its oncology, liver disease, inflammatory, and sexual dysfunction programs.
Recent news has highlighted pivotal and mid-stage clinical studies, including a Phase III trial of Namodenoson in advanced hepatocellular carcinoma, a Phase IIb trial in MASH, and a Phase IIa study in pancreatic cancer. The company has also reported compassionate use cases in advanced liver disease and cirrhosis, as well as long-term survival outcomes in liver cancer patients treated with Namodenoson. For Piclidenoson, updates include Phase III psoriasis development and protocol preparation for rare diseases such as Lowe Syndrome, along with preclinical findings in vascular dementia models.
News items also cover CF602, an A3AR allosteric modulator in development for erectile dysfunction, including patent allowances and grants in markets such as Brazil, the United States, and Europe. Can-Fite regularly reports on its intellectual property strategy, out-licensing and distribution agreements for human and veterinary indications, participation in industry conferences, and capital markets activities such as public offerings, warrant amendments, and share structure changes like reverse splits and ADS ratio adjustments.
Investors and observers can use this CANF news feed to monitor key milestones that may affect the company’s clinical pipeline, regulatory interactions, partnering discussions, and financial position over time.
Can-Fite BioPharma (NYSE American: CANF) announced the successful completion of pre-clinical studies showing that its CBD-rich T3/C15 cannabis fraction has an inhibitory effect on liver fibrosis. This condition, associated with severe liver diseases like NAFLD and HCC, involves the excessive buildup of scar tissue in the liver. The studies revealed that the therapeutic effects are mediated through the A3 adenosine receptor (A3AR). Can-Fite's drug candidate Namodenoson is progressing to pivotal Phase III trials for liver cancer and Phase IIb for NASH, with patent applications filed for cannabinoid-based therapies.
Can-Fite BioPharma (NYSE American: CANF, TASE: CFBI) has published a webinar focusing on its drug candidate Namodenoson for treating NASH, hosted by CEO Dr. Pnina Fishman and featuring KOL Dr. Stephen Harrison. Namodenoson successfully completed a Phase II study for NAFLD/NASH, and the company is preparing a Phase IIb study. Dr. Harrison emphasized the drug's potential in treating NASH, especially in high-risk patients. Can-Fite is actively pursuing regulatory pathways for accelerated approval based on its clinical results.
Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) announced the publication of a scientific paper on its drug Namodenoson for advanced hepatocellular carcinoma (HCC) with Child-Pugh B cirrhosis. Although the Phase II trial did not meet its primary endpoint, it showed significant survival benefits for patients with a CPB score of 7, with some patients remaining under treatment for over 3.5 years. The FDA and EMA have approved the protocol for a Phase III study. Namodenoson has received Orphan Drug and Fast Track Designation from the FDA.
Can-Fite BioPharma Ltd (NYSE American: CANF, TASE: CFBI) has received approval from Israel's Ministry of Health to conduct pre-clinical studies on cannabinoid fractions at nanomolar concentrations. This assessment aims to explore effects on cancer, inflammatory, and fat cells, potentially minimizing the adverse effects associated with higher concentrations. Can-Fite's research will be conducted in its labs, utilizing patent-pending formulations and assays. The medical cannabis market, projected to grow at a CAGR of 29%, positions Can-Fite strategically for advancements in this emerging field.
Can-Fite BioPharma Ltd. (NYSE American: CANF) announced progress on its drug candidate Namodenoson for treating non-alcoholic steatohepatitis (NASH). The company is designing a Phase IIb study with expert collaboration, following a successful Phase II study. Manufacturing for the clinical trial is complete, and new NASH patents have been issued. Namodenoson is licensed for distribution in Korea and China, targeting a growing market projected at $35-40 billion by 2025. Current estimates indicate 17%-33% of the U.S. population has non-alcoholic fatty liver disease (NAFLD), emphasizing the urgent medical need.
Can-Fite BioPharma (NYSE American: CANF) announced its participation in the 12th annual LD 500 Virtual Conference, scheduled for September 1, 2020. CEO Dr. Pnina Fishman will present at 9:20 AM EST and conduct private meetings with investors. The event aims to attract around 20,000 attendees and features 300 companies. Can-Fite plans to update on its advanced pipeline, including Phase III trials for rheumatoid arthritis, psoriasis, and liver cancer, alongside new studies for COVID-19 and NAFLD/NASH. Investors can register to view the presentation online.